CN100406554C - Colibacillus containing human source guide suppository dissolving antibody gene and its secretion producg - Google Patents

Abstract

The present invention relates to colibacillus containing a specificity guide thrombolysis antibody gene of a human source anti D-dimer, and secretion products thereof. The present invention is characterized in that a heavy chain gene and a light chain gene of the human antibody are connected to a bacterial virus plasmid pComb3Htype to form a recombinant phage plasmid pComb3H-HL by using a semi-jacket type PCR method. The recombinant phage plasmid is built into a phage antibody combined library under the superinfection of helper phage VCSM13; a specificity strain of the D-dimer of an anti-human fibrin breakdown product is screened by an ELISA method. Consequently, the antibody has the immunity on the D-dimer specificity of a thrombi degradation matter, can form a thrombolytic agent together with thrombolysis medicines and has wide clinical application value for treating embolic diseases of blood vessels.

Description

A kind of intestinal bacteria and secretory product thereof that contains people source targeting thrombolysis antibody gene

Technical field:

The present invention relates to the intestinal bacteria and the secretory product thereof of the dimeric specificity targeting thrombolysis of the anti-D-in a kind of people of containing source antibody gene.

Background technology:

Thrombus, recovering blood flow unobstructed is the effective means of vessel embolism such as treatment acute myocardial infarction and cerebral infarction.(Urokinase UK) is clinical efficient thrombolysis medicine commonly used for tissue plasminogen activator (t-PA), urokinase.But there is more t-PA bind receptor in other position histocyte of human body, can reduce the concentration of t-PA in the circulation, and its therapeutic action is weakened.And the increasing dosage, not only treating cost improves, and heavy dose of t-PA or UK also can activate the Profibrinolysin in the circulation blood, scleroproein, α in the degraded circulation blood ₂Blood coagulation substances such as-antiplasmin, factor V, VIII and thrombocyte GP IIb/IIIa receptor complex cause the general bleeding tendency.Many documents and materials report targeting thrombolysis are also arranged in recent years, but its curative effect is also unsatisfactory, the defective that mainly has the following aspects: (1) is many based on scleroproein in the selection of thrombus target mark, and the specific antigens determining area of scleroproein beta chain N end is partly covered or is lost with fibrinous polymerization in early days at thrombolysis, has reduced the target of fibrin monomer.(2) the preparation quadroma technology that monoclonal antibody adopted, the poor stability of antibody producing.(3) monoclonal antibody of hybridoma technology production mostly is mouse source property, and molecular weight is big, and the people is had immunogenicity, reduces the thrombolysis effect, even can cause severe anaphylactic reaction.(4) the guiding preparation adopts Chemical Crosslinking Methods to connect monoclonal antibody specific and thrombolytics more, and the chemically modified effect of its chemically crosslinked can reduce combining of antibody and thrombus position, and causes the active reduction of thrombolytics.Therefore, it is just very necessary to study a kind of directed agents of novel thrombolytic drug.

D-dimer (D-Dimer, DD) in the thrombosis process, link to each other with the core of thrombus always, its not crested of antigenicity, be that γ-γ chain that crosslinked fibrin degraded forms is main fibrin-specific degraded product, be the minimal segment in the fibrin degradation product (FDP), in normal human blood, there is not this thing substantially, be unique direct reflection zymoplasm and plasmin generated ideal index, just can occur in a large number in the blood when the fibrinolytic effect strengthens, the increase blood coagulation and the dual of fibrinolytic system that show body of its content are activated in succession.Therefore the D-dimer can be used as one of molecular marker of interior hypercoagulative state of body and secondary hyperfibrinolysis.

The appearance of display technique of bacteriophage (phage display) has benefited from designing a complete set of immune globulin variable region gene of one group of primer amplification artificially with the method for PCR, and the success of providing the immunoglobulin molecules of identification, conjugated antigen ability at the expression in escherichia coli justacrine.Since the eighties in 20th century, display technique of bacteriophage proposes and is widely used in later time through Dullbeclo, becomes the novel method of a preparation specific antibody, is a kind of genetic expression triage techniques.It provides an effective means of separating goal gene from antibody library, and goal gene can be cloned in the particular expression carrier, and exogenous genes products and coat protein are merged, and is illustrated in the filobactivirus surface.Can walk around the hybridoma approach, even not have the human monoclonal antibody of diagnosis and therapeutic value, aspect newtype drug design, development guiding transfer system, have broad application prospects through the immunity preparation.

PComb3H is the plasmid that is exclusively used in the expressing antibodies gene.Phage pComb3H plasmid has ampicillin resistance gene.PComb3H expresses in intestinal bacteria XL1-Blue usually.The Fd-PIII antigen-4 fusion protein gene of phage is translated into the cytolemma gap that is imported into bacterium behind the albumen by the pelB leader, heavy chain Fd is embedded on the film by merging with PIII, and light chain is directed into intermembrane space by ompA, and there is good well-oxygenated environment in the cytolemma gap, make heavy chain and light chain be formed good stable disulfide linkage and form the Fab that function is arranged, because the synthetic of its coat protein also is by above-mentioned similar approach behind the phage-infect bacterium, causes functional Fab antibody can be assembled in phage surface.

Technology contents:

In order to solve the guidance quality problem of thrombolytic drug, the invention provides: the intestinal bacteria of the dimeric specificity targeting thrombolysis of the anti-D-in a kind of people of generation source antibody, it is characterized in that by half sleeve type PCR method the heavy chain gene of people's antibody and light chain gene being connected into phage plasmid pComb3H forms recombinant phage plasmid pComb3H-HL, recombinant phage plasmid pComb3H-HL is built into the phage antibody combinatorial library under the superingection of helper phage VCSM13; Filter out the dimeric special strain of anti-human fibrin degraded product D-through the ELISA method.

In order to obtain people source targeting thrombolysis antibody.At first through pcr amplification discrepancy immunoglobulin gene: the lymphocyte in the separation of human peripheral blood, extract cell total rna with TRJZOL solution, be used for the synthetic of cDNA.Amplimer is changed with reference to the sequence of reports such as Kang carries out the PCR first time, be composed of 32 pairs of primers with 4 groups of Fd leading peptide primers and 8 groups of variable region of heavy chain 3 ' end primers, Kappa chain variable region leading peptide primer and 3 ' the end primer pairing of Kappa chain variable region, Lambda chain variable region leading peptide primer and 3 ' the end primer pairing of Lambda chain variable region.

PCR primer for the first time:

● people source heavy chain Fd primer

1) variable region of heavy chain leading peptide primer

506-1 5’-ATG?GAC?TAA?ACC?TGG?AGG(A/G)TC?(C/T)TC?T(G/T)C-3’

506-2 5’-ATG?GAG?(C/T)TT?GGG?CTG?A(G/C)G?TGG(G/C)TT?T(C/T)T-3’

506-3 5’-ATG(A/G)A(A/C)(A/C)(A/T)ACT(G/T)TG(G/T)(A/T)(G/C/T)C(A/T)(C/T)(G/C)

CT(C/T)C(C/T)G-3’

2) variable region of heavy chain 3 ' end primer

CA1 5’-AGT?TGA? ACT?AGT?TGG?GCA?GGG?CAC?AGT?CAC-3’

CE1 5’-GCT?GAA? ACT?AGT?TTT?GTC?GAC?CCA?GTC?TGT?GGA-3’

CD1 5’-TGC?CTT? ACT?AGT?CTC?TGG?CCA?GCG?GAA?GAT-3’

CG4A 5’-GCA?TGA? ACT?AGT?TGG?GGG?ACC?ATA?TTT?GGA-3’

CG2A 5’-CTC?GAC? ACT?AGT?TTT?GCG?CTC?AAC?TGT?CTT-3’

CG3A 5’-TGT?GTG? ACT?AGT?GTC?ACC?AAG?TGG?GGT?TTT-3’

CG1Z 5’-GCA?TGT? ACT?AGT?TTT?GTC?ACA?AGA?TTT?GGG-3’

CM1 5’-GCT?CAC? ACT?AGT?AGG?CAG?CTC?AGG?AAT?CAC-3’

● people's endogenous light chain primer

3) Kappa chain variable region leading peptide primer

506-45’-ATG?GAC?ATG(AG)(AG)(AG)(AGT)(CT)C?C(ACT)(AGC)?G(CT)(GT)?CA(GC)?CTT-3’

4) Kappa chain variable region 3 ' end primer

Ck1Z 5’--GCG?CCG? TCT?AGA?ACT?AAC?ACT?CTC?CTC?TGT?TGA?AGC?TCT?TTG?TGA?CGG?GCG?ATC?TCA?G-3’

5) Lambda chain variable region leading peptide primer

507-15’-ATG?(TG)CC?TGG?(AT)C(CT)?CCT?CTC?(CT)T?(CT)?CT(CG)?(AT)(CT)C-3’

6) Lambda chain variable region 3 ' end primer

CLZ 5’-CGC?CG T?CTA?GAA?TTA?TGA?ACA?TTC?TGT?AGG-3’

Getting for the first time, the PCR product carries out the amplification second time as template, be composed of 40 counterweight strand primers with 5 groups of variable region of heavy chain, 5 ' end primer and 8 groups of variable region of heavy chain 3 ' end primers, be composed of two pairs of Kappa strand primers with 2 groups of Kappa chain variable regions, 5 ' end primer and Kappa chain variable region 3 ' end primer, be composed of 8 pairs of Lambda strand primers with 8 groups of Lambda chain variable regions, 5 ' end primer and Lambda chain variable region 3 ' end primer.Contain XhoI restriction enzyme site (CTCGAG) in variable region of heavy chain 5 ' the end primer, variable region of heavy chain 3 ' end primer contains SpeI restriction enzyme site (ACTAGT), variable region of light chain 5 ' end primer contains SacI restriction enzyme site (GAGCTC), and light chain Ke Jiao district 3 ' end primer contains XbaI enzyme cutting site (TCTAGA).

PCR primer for the second time:

● people source heavy chain Fd primer

1) variable region of heavy chain 5 ' end primer

VH13A 5’-AG?GTG?CAG? CTC?GAG?(C/G)AG?TCT?GGG-3’

H58 5’-CAG?GTA?CAG?CTG? CTC?GAG?TCA?GGT?CCA-3’

VH134F 5’-AG?GTG?CAG?CTG? CTC?GAG?TC(T/G)?GG-3’

VH4FG 5’-CAG?GTG?CAG?CT(A/G)? CTC?GAG?TCT?GG-3’

VH6A 5’-CAG?GTA?CAG? CTC?GAG?CAG?TCA?GG-3’

2) variable region of heavy chain 3 ' end primer

CA1 5’-AGT?TGA? ACT?AGT?TGG?GCA?GGG?CAC?AGT?CAC-3’

CE1 5’-GCT?GAA? ACT?AGT?TTT?GTC?GAC?CCA?GTC?TGT?GGA-3’

CD1 5’-TGC?CTT? ACT?AGT?CTC?TGG?CCA?GCG?GAA?GAT-3’

CG4A 5’-GCA?TGA? ACT?AGT?TGG?GGG?ACC?ATA?TTT?GGA-3’

CG2A 5’-CTC?GAC? ACT?AGT?TTT?GCG?CTC?AAC?TGT?CTT-3’

CG3A 5’-TGT?GTG? ACT?AGT?GTC?ACC?AAG?TGG?GGT?TTT-3’

CG1Z 5’-GCA?TGT? ACT?AGT?TTT?GTC?ACA?AGA?TTT?GGG-3’

CM1 5’-GCT?CAC? ACT?AGT?AGG?CAG?CTC?AGG?AAT?CAC-3’

● people's endogenous light chain primer

3) Kappa chain variable region 5 ' end primer

HK53 5’-GAT?ATT? GAG?CTC?ACT?CAG?TCT?CCA-3’

VKIS 5’-GAC?ATC? GAG?CTC?ACC?CAG?TCT?CC-3’

4) Kappa chain variable region 3 ' end primer

HK35’-GCG?CCG? TCT?AGA?ACT?AAC?ACT?CTC?CCC?TGT?TGA?AGC?TCT?TTG?TGA?CGG?GCG?ATC?TCA?G-3’

5) Lambda chain variable region 5 ' end primer

HL51 5’-AAT?TTT? GAG?CTC?ACT?CAG?CCC?CAC-3’

HL53 5’-TCT?GTG? GAG?CTC?CAG?CCG?CCC?TCA?GTG-3’

HL56 5’-CAG?TCT? GAG?CTC?ACT?CAG?GAG?CCC-3’

VL5.7 5’-CAG?(G/T)(C/T)T? GAG?CTC?AC(G/T)?CA(A/G)CCG?CCC-3’

VL1GP 5’-AAT?TTT? GAG?CTC?ACT?CAG?CCC?CCC?TCT?GTG?TC-3’

VL2 5’-TCT?G(A/C/T)(A/C/G)? GAG?CTC?CAG(C/G)(A/C)(C/G/T)(C/G)C(C/T)(G/T)(C/T)(A/C/T)

GTG-3’

VL5.8 5’-CAG(A/G/T)CT? GAG?CTC?ACG?CAG(C/G)(A/C)G(C/T)C(C/T)TCC-3’

VL2.3 5’-TCT?G(C/T)(C/G)? GAG?CTC?CAG?CC(T/G)(C/G)CC?TC(A/C)GTG-3’

6) Lambda chain variable region 3 ' end primer

HL3 5’-CGC?CG T?CTA?GAA?CTA?TGA?ACATTC?TGT?AGG-3’

The structure that contains the phage plasmid pComb3H-HL of human immunoglobulin heavy chain's gene and light chain gene.The light chain amplified production is through the SacI-XbaI double digestion, and pComb3H is also through the SacI-XbaI double digestion, and the T4DNA ligase enzyme connects light chain gene and pComb3H, constitutes pComb3H-L.The heavy chain amplified production is through the XhoI-SpeI double digestion, and pComb3H-L connects with the T4DNA ligase enzyme also through the XhoI-SpeI double digestion, constitutes pComb3H-HL.

The strain of the dimeric pComb3H-HL phage of anti-human fibrin degraded product D-is screened in enrichment.With the soda-sodium bicarbonate solution bag of pH9.6 by the D-dimer, phage antibody library is adsorbed on, to not adsorb or adsorb not tight phage antibody through piping and druming siphons away, adsorb phage antibody closely with glycine-hydrochloric acid elution buffer of pH2.2 and Tris eluant solution and neutralization respectively, adding intestinal bacteria XL1-Blue hatched 1 hour, add helper phage VCSM13 cultivation again, but utilize the proliferative amplification phage antibody special of phage the D-dimer.

With pComb3H-HL/XL1-Blue system expression antibody.With the SpeI-NheI double digestion geneIII gene and subsequent terminator are cut, utilizing SpeI and NheI is the relation of isoschizomers, with ligase enzyme linear plasmid is connected into ring, and in intestinal bacteria XL1-Blue, express, owing to lacked the geneIII gene, can not express piii protein, phage can't be assembled, can only give expression to the heavy chain fragment and the light chain segments of antibody, these two fragments are directed peptide and are inducted into kytoplasm and are assembled into Fab between week.

Through ELISA and Western blotting checking, the antibody that screening reaches at expression in escherichia coli from phage antibody library really has resistance and specificity to human fibrin degraded product D-dimer.

The intestinal bacteria of the above-mentioned pComb3H-HL of containing are handed over " Chinese typical culture collection center (Wuhan) " preservation, preserving number CCTCC NO:M203009

In sum, the present invention has obtained a kind of people source targeting thrombolysis antibody, and this antibody has specific binding capacity to human fibrin degraded product D-dimer.Therefore, this antibody capable combines with thrombolytic drug, is directed on the thrombus thrombolytic drug is single-minded, concentrates the effect of performance thrombolytic drug, has avoided the invalid release of medicine, is a kind of directed agents of thrombolysis efficiently.Has high clinical value.

Above-mentioned engineering bacteria can be secreted and contain following human antibody light-chain amino acid sequence, it is characterized in that:

S V S E S P G K T V T I S C T

G S S G S I A S N Y V Q W Y R

Q R P G S A P T T V I Y E D N

Q R P S G V P D R F S G S I D

S S T N S A S L T I S G L K T

E D E A D Y Y C Q S Y D S S N

W V F G G G T K L T V L G Q P

K A A P S V T L F P P S S E E

L Q A N K A T L V C L I S D F

Y P G A V T V A W K A D S S P

V K A G V E T T T P S K Q S N

N K Y A A S S Y L S L T P E Q

W E S H K S Y S C Q V T H E G

S T V E K T V A

The gene order of the light chain of above-mentioned people source targeting thrombolysis antibody is characterized in that:

TCTGTGTCGGAGTCTCCGGGGAAGACGGTAACCATCTCCTGCACC

GGCAGCAGTGGCAGCATTGCCAGCAACTATGTGCAGTGGTACCGG

CAGCGCCCGGGCAGTGCCCCCACCACTGTGATCTATGAGGATAAC

CAAAGACCCTCTGGGGTCCCTGATCGGTTCTCTGGCTCCATCGAC

AGCTCCACCAACTCTGCCTCCCTCACCATCTCTGGACTGAAGACT

GAGGACGAGGCTGACTACTACTGTCAGTCTTATGATAGCAGCAAT

TGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAGGTCAGCCC

AAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAG

CTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTC

TACCCGGGAGCCGTGACGGTGGCCTGGAAGGCAGATAGCAGCCCC

GTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAAC

AACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCTGAGCAG

TGGGAGTCCCACAAAAGCTACAGCTGCCAGGTCACGCATGAAGGG

AGCACCGTGGAGAAGACAGTGGCC

Above-mentioned engineering bacteria can be secreted and contain following human antibody heavy chain amino acid sequence, it is characterized in that:

E S G G G V V Q P G R S L R L

S C A A S G F T F S S Y A M S

W V R Q A P G K G L E W V S A

I S G S G G S T Y Y A D S V K

G R F T I S R D N S K N T L Y

L Q M D S L R A E D T A V Y Y

C A K P H G R Y Y D S S G Y R

T Y F D Y W G Q G T L V T V S

S G S A S A P T L F P L V S C

E N S P S D T S S V A V G C L

A Q D F L P D S I T F S W K Y

K N N S D I S S T R G F P S V

L R G G K Y A A T S Q V L L P

S K D V M Q G T D E H V V C K

V Q H P N G N K E K N V P L P

V I A E L P

The gene order of the heavy chain of above-mentioned people source targeting thrombolysis antibody is characterized in that:

GAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC

TCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGC

TGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCT

TTAGATGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAG

GGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT

CTGCAAATGGACAGCCTGAGAGCCGAGGACACGGCCGTATATTAC

TGTGCGAAGCCCCACGGGCGATACTATGATAGTAGTGGTTATCGA

ACCTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCC

TCAGGGAGTGCATCCGCCCCAACCCTTTTCCCCCTCGTCTCCTGT

GAGAATTCCCCGTCGGATACGAGCAGCGTGGCCGTTGGCTGCCTC

GCACAGGACTTCCTTCCCGACTCCATCACTTTCTCCTGGAAATAC

AAGAACAACTCTGACATCAGCAGCACCCGGGGCTTCCCATCAGTC

CTGAGAGGGGGCAAGTACGCAGCCACCTCACAGGTGCTGCTGCCT

TCCAAGGACGTCATGCAGGGCACAGACGAACACGTGGTGTGCAAA

GTCCAGCACCCCAACGGCAACAAAGAAAAGAACGTGCCTCTTCCA

GTGATTGCAGAGCTGCCT

Description of drawings:

Fig. 1 recombinant plasmid pComb3H-HL structural representation

Fig. 2 people Kappa chain fragment PCR electrophorogram

Embodiment: the present invention further sets forth by following examples.

The extraction of lymphocytic separation and purification and cell total rna

Extract human peripheral, use the lymphocyte separation medium isolated lymphocytes, extract cell total rna according to ordinary method.With the resuspended RNA of the pure water of no RNAase, place ice bath be used for cDNA synthetic or put-70C preserves.(annotate: patient and normal people's blood mixes respectively separately, extracts total RNA)

The above-mentioned RNA5ul that extracts from lymphocyte is placed the Eppendorf pipe of no RNAase, system composed as follows:

Oliga(dT) 1μl

RNA 5μl

DEPC treating water 4 μ l

The Eppendorf pipe is placed 65 ℃ of 5min, put ice bath then. with preceding cDNA is being synthesized damping fluid vibration 5s.Prepare following reaction system:

5 * cDNA synthesizes damping fluid 4 μ l

O．1M?DTT 1μl

RNAase inhibitor 1 μ l

DEPC treating water 1 μ l

10mM?dNTP?Mix 2μl

ThermoScript II

S _CRIPTRT 1 μ l

total 10μl

Above-mentioned reaction mixture is added in each RNA primer mixing tube of putting ice bath, put 50 ℃ 20～50 minutes.Put 85 ℃ of 5 minutes termination reactions. instantaneous centrifugal, add l μ l RNAaseH in each reaction tubes, 37 ℃ were reacted 20 minutes.Be used for PCR or-20 ℃ of prolonged preservation at once.

Half sleeve type PCR amplification Fab antibody gene

The cDNA that adopts patient and normal people respectively is a template, with above-mentioned first time of PCR primer amplification.Program is as follows: behind 94 ℃ of sex change 5min, add the TeqDNA polysaccharase, 94 ℃ of sex change 1min again, heat drop 55 ℃～45 ℃ annealing that fall are extended 1min for 1min.72 ℃, after 10 circulations, and 94 ℃ of sex change 1min again.48 ℃ of annealing 1min, 72 ℃ are extended 1min, and after 15 circulations, 72 ℃ are extended 5min.

Reaction system is as follows:

Signal peptide end primer 0.5 μ l

3 ' end primer, 0.5 μ l

10 * PCR damping fluid, 2 μ l

dNTPs 1μl

Deionized water 14 μ l

cDNA 1μl

Taq enzyme 1 μ l

Total 20μl

The PCR product of getting above-mentioned preparation is that template is carried out the PCR reaction second time.Earlier at 94 ℃ of sex change 5min, adds the TaqDNA polysaccharase then before the PCR circulation, 94 ℃ of sex change 1min again, heat drop 62 ℃～50 ℃ annealing 1min that fall, 72 ℃ are extended 1min, after 12 circulations, and 94 ℃ of sex change 1min again, 54 ℃ of annealing 1min, 72 ℃ are extended 1min, and after 20 circulations, 72 ℃ are extended 5min.

Reaction system is as follows:

5 ' end primer, 1 μ l

3 ' end primer, 1 μ l

10 * PCR damping fluid, 5 μ l

dNTPs 1μl

Deionized water 40 μ l

cDNA 1μl

Taq enzyme 1 μ l

Total 50μl

Get the PCR product and carry out electrophoretic analysis, the result shows that all the purpose band of acquisition～700bp (shown in Figure 2ly is people's antibody Lambda chain fragment PCR products electrophorogram, " 1～8 " is respectively the PCR product of primer to HL3/HL51, HL3/HL53, HL3/HL56, HL3/VL5.7, HL3/VL1GP, HL3/VL2, HL3/VL5.8 and HL3/VL2.3, " 9 " negative contrast, " 10 " are 100bp Marker)

The structure of phage antibody library

Carrier pComb3H DNA and purified light chain PCR product are cut with Xba I and Sac I enzyme respectively, and the T4DNA ligase enzyme connects, 16 ℃ 12～16 hours.Electricity transformed competence colibacillus bacterium XL1-Blue spends the night in the SOC culture medium culturing.Get 1 μ l nutrient solution and dilute 100 times, 1000 times respectively and coat the LB flat board that contains 100 μ g/ml penbritins, to detect transformation efficiency.All the other bacterium liquid change 10mlSB (containing Amp20 μ g/ml) substratum over to, 37 ℃ of shaking culture 1 hour.Add 140ml SB (containing Amp100 μ g/ml), 37 ℃ of shaking culture are spent the night.Extract recombinant plasmid pComb3H-L DNA next day, carry out following operation:

1. identify and insert efficient.20 clones of picking at random, identify recombination fraction with bacterium colony PCR method: in super clean bench with toothpick 20 bacterium colonies of picking at random from 37 ℃ of LB flat boards that spend the night of sterilizing, sneak into and contain in the 20 μ lPCR reaction systems that prepared, 94 ℃ of sex change 5min, 94 ℃ of 30s again, 54 ℃ of 40s, 72 ℃ of 50s, 35 circulations are extended 10min for back 72 ℃.With the PCR product in fresh TAE damping fluid with 2% agarose gel electrophoresis, amplify the fragment person about 680bp, be recombinant clone.

Identify the primer of light chain recombination fraction:

5 ' end, 5 '-GGC TGG TTT CGC TAC CGT GGC CCA G-3 '

3 ' end, 5 '-GCT GCC GTA GGC AAT AGG TAT TTC A-3 '

Identify the primer of heavy chain recombination fraction:

5 ' end, 5 '-CTG CCC AAC CAG CCA TGG CCG AAG-3 '

3 ' end, 5 '-CCT CCT GGC CGG CCT GGC CAC TAG-3 '

2. the foundation of the clone of heavy chain gene and phage antibody library.Above-mentioned purified heavy chain Fd PCR product is carried out Xho I and Spe I endonuclease reaction respectively with the pComb3H-L that contains light chain gene.

Connection, conversion and authentication method are the same.Obtain recombinant plasmid pComb3H-HL (Fig. 1).

The enrichment screening of phage antibody library

Is 10 μ g/ml with the D-dimer with 0.1mmol/l yellow soda ash-sodium bicarbonate (PH9.6) solution dilution, every hole 50 μ l, and 4 ℃ are spent the night.Adsorption antigen not in the next day flush away plate was with 37 ℃ of sealings of 3%BSA-PBS 1 hour.Abandon confining liquid, in every hole, add 70 μ l phage antibody libraries, hatched 2 hours for 37 ℃.Abandon Kong Zhongwei in conjunction with phage, wash each hole with TBS/Tween 20 solution, wash altogether 10 times, the available pipettor that has suction nozzle is blown and beaten every hole repeatedly, but is sure not excessively.With distillation washing twice, the liquid in every hole is blotted.Every hole adds 50 μ l glycine-hydrochloric acid (pH2.2) elution buffers, and incubated at room 10 minutes is blown and beaten every hole repeatedly with the pipettor suction nozzle during this period, notes being sure not to blow out too much bubble.Add 3～5 μ l2mol/lTris, the pH value that makes solution about 7, the phage solution that elutes with neutralization.The about OD that adds the 2ml prepared fresh immediately ₆₀₀=0.7～1.3 E.coli XL1-Blue bacterium, incubated at room 15～20 minutes.Change in the 200ml triangular flask, add the SB substratum that contains 20 μ g/ml penbritins, 10 μ g/ml tsiklomitsins, get 1 μ l immediately, 0.1 μ l, 0.01 μ l is coated with the phage that LB ammonia benzyl plate elutes with titration, rest part adds 100ml and contains 100 μ g/ml penbritins, 37 ℃ of shaking culture of the SB substratum of 10 μ g/ml tsiklomitsins 1 hour.Add 10 ¹²The helper phage VCSM13 of pfu, 37 ℃ of shaking culture 2 hours.Add kantlex 70 μ g/ml, 37 ℃ of shaking culture are spent the night.Repeat above enrichment screening step 2 wheel.Through two take turns enrichment screening after, with the competence XL1-Blue bacterium of the phage-infect prepared fresh that elutes, after 37 ℃ of incubated overnight, preserving longly has the plate of single bacterium colony stand-by in 4 ℃.

Anti-D-dimer MONOCLONAL ANTIBODIES SPECIFIC FOR

The competence XL1-Blue bacterium of the phage-infect prepared fresh that elutes after the last enrichment, after 37 ℃ of incubated overnight, growing 60 bacterium colonies of picking on the plate that single bacterium colony is arranged, be inoculated into 2ml and contain 100 μ g/ml penbritins, in the SB substratum of 10 μ g/ml tsiklomitsins, 37 ℃ of incubated overnight.Be inoculated in 10ml with 1:50 next day and contain 100 μ g/ml penbritins, in the SB substratum of 10 μ g/ml tsiklomitsins, 37 ℃ are cultured to OD=0.1～0.5, add helper phage, continue overnight incubation.Next day, the centrifuging and taking supernatant was phage antibody.Supernatant with 4%PEG8000 and 3%Nacl simmer down to 200 μ l, is deposited in-20 ℃.The screening of anti-D-dimer phage antibody is undertaken by the recombinant phages antibody identification kit specification sheets available from Amersham phamacia company.

The solubility expression of Fab antibody in prokaryotic cell prokaryocyte

Positive colony after above-mentioned enrichment screening after 37 ℃ of incubated overnight, extracts plasmid DNA and measures DNA concentration.Get 1 μ g plasmid DNA, cut digestion, the postdigestive single band of electrophoresis purifying, the about 4700bp of molecular weight through SpeI and NheI enzyme.Resuspended DNA adds 2U ligase enzyme and corresponding connection damping fluid in sterilized water, in total amount 20 μ l systems, 16 ℃ of connections are spent the night.With above-mentioned connection product transformed competence colibacillus host bacterium XL1-Blue.The single bacterium colony of picking is cultivated the amplification back and is extracted plasmid DNA, and whether detect the geneIII gene cut: with XhoI and NotI double digestion, should cut out the fragment of about 700bp, still exist as the geneIII gene, then cut out the fragment of about 1200bp.Get above-mentioned positive bacterial classification 10 μ l and inoculate into 4mlSB nutrient solution (containing 100 μ g/ml penbritins), after 37 ℃ of incubated overnight, transferred species is in 50mlSB nutrient solution (containing 100 μ g/ml penbritins), and 37 ℃ of shaking culture are to OD=0.1～0.3.Add 1mmol/L IPTG, put 30 ℃ of shaking culture about 10～12 hours.4 ℃ of 4000r/min are centrifugal 15 minutes.Abandon supernatant, with the resuspended bacterial precipitation of 1/10 volume PBS (pH7.4), ultrasonication, program is set to: power 300W, and ultrasonic 4s, 4s intermittently, repeating 99 times is 1 circulation, totally 2～3 circulates.4 ℃ of 10000r/min are centrifugal 20 minutes.Supernatant promptly contains the solubility Fab antibody of expression.

Ab sequence electronic edition WU

＜110〉Chen Min gives birth to the yellow Xiang Tian Chaowei Yang Xiao instrument Chen Ying indigo plant of overflowing of Wu Wenyan Huang Shaohua

＜120〉the dimeric specificity targeting thrombolysis of a kind of anti-D-in people source antibody

<160>4

<210>1

<211>693

<212>DNA

＜213〉ethnic group IgF ab heavy chain

<220>

<221>allele

<222>(1)..(693)

<220>

<221>CDS

<222>(1)...(693)

<400>1

gagtctgggg?gaggcgtggt?ccagcctggg?aggtccctga?gactctcctg?tgcagcctct?60

ggattcacct?ttagcagcta?tgccatgagc?tgggtccgcc?aggctccagg?gaaggggctg?120

gagtgggtct?cagctattag?tggtagtggt?ggtagcacat?actacgcaga?ctccgtgaag?180

ggccggttca?ccatctccag?agacaattcc?aagaacacgc?tgtatctgca?aatggacagc?240

ctgagagccg?aggacacggc?cgtatattac?tgtgcgaagc?cccacgggcg?atactatgat?300

agtagtggtt?atcgaaccta?ctttgactac?tggggccagg?gaaccctggt?caccgtctcc?360

tcagggagtg?catccgcccc?aacccttttc?cccctcgtct?cctgtgagaa?ttccccgtcg?420

gatacgagca?gcgtggccgt?tggctgcctc?gcacaggact?tccttcccga?ctccatcact?480

ttctcctgga?aatacaagaa?caactctgac?atcagcagca?cccggggctt?cccatcagtc?540

ctgagagggg?gcaagtacgc?agccacctca?caggtgctgc?tgccttccaa?ggacgtcatg?600

cagggcacag?acgaacacgt?ggtgtgcaaa?gtccagcacc?ccaacggcaa?caaagaaaag?660

aacgtgcctc?ttccagtgat?tgcagagctg?cct 693

<210>2

<211>640

<212>DNA

＜213〉ethnic group IgF ab light chain

<221>allele

<222>(1)...(640)

<220>

<221>CDS

<222>(1)...(640)

<400>2

actcagcccc?actctgtgtc?ggagtctccg?gggaagacgg?taaccatctc?ctgcaccggc?60

agcagtggca?gcattgccag

cagtggtacc?ggcagcgccc 120

cccaccactg?tgatctatga?ggataaccaa?agaccctctg?gggtccctga?tcggttctct?180

ggctccatcg?acagctccac?caactctgcc?tccctcacca?tctctggact?gaagactgag?240

gacgaggctg?actactactg?tcagtcttat?gatagcagca?attgggtgtt?cggcggaggg?300

accaagctga?ccgtcctagg?tcagcccaag?gctgccccct?cggtcactct?gttcccgccc?360

tcctctgagg?agcttcaagc?caacaaggcc?acactggtgt?gtctcataag?tgacttctac?420

ccgggagccg?tgacggtggc?ctggaaggca?gatagcagcc?ccgtcaaggc?gggagtggag?480

accaccacac?cctccaaaca?aagcaacaac?aagtacgcgg?ccagcagcta?cctgagcctg?540

acgcctgagc?agtgggagtc?ccacaaaagc?tacagctgcc?aggtcacgca?tgaagggagc?600

accgtggaga?agacagtggc?ccctacagaa?tgttcatagt 640

<210>3

<211>231

<212>PRT

＜213〉ethnic group IgF ab heavy chain

<400>3

Glu?Ser?Gly?Gly?Gly?Val?Val?Gln?Pro?Gly?Arg?Ser?Leu?Arg?Leu

1?5?10?15

Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Ser?Ser?Tyr?Ala?Met?Ser

20?25?30

Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu?Trp?Val?Ser?Ala

35?40?45

Ile?Ser?Gly?Ser?Gly?Gly?Ser?Thr?Tyr?Tyr?Ala?Asp?Ser?Val?Lys

50?55?60

Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ser?Lys?Asn?Thr?Leu?Tyr

65?70?75

Leu?Gln?Met?Asp?Ser?Leu?Arg?Ala?Glu?Asp?Thr?Ala?Val?Tyr?Tyr

80?85?90

Cys?Ala?Lys?Pro?His?Gly?Arg?Tyr?Tyr?Asp?Ser?Ser?Gly?Tyr?Arg

95?100?105

Thr?Tyr?Phe?Asp?Tyr?Trp?Gly?Gln?Gly?Thr?Leu?Val?Thr?Val?Ser

110?115?120

Ser?Gly?Ser?Ala?Ser?Ala?Pro?Thr?Leu?Phe?Pro?Leu?Val?Ser?Cys

125?130?135

Glu?Asn?Ser?Pro?Ser?Asp?Thr?Ser?Ser?Val?Ala?Val?Gly?Cys?Leu

140?145?150

Ala?Gln?Asp?Phe?Leu?Pro?Asp?Ser?Ile?Thr?Phe?Ser?Trp?Lys?Tyr

155?160?165

Lys?Asn?Asn?Ser?Asp?Ile?Ser?Ser?Thr?Arg?Gly?Phe?Pro?Ser?Val

170?175?180

Leu?Arg?Gly?Gly?Lys?Tyr?Ala?Ala?Thr?Ser?Gln?Val?Leu?Leu?Pro

185?190?195

Ser?Lys?Asp?Val?Met?Gln?Gly?Thr?Asp?Glu?His?Val?Val?Cys?Lys

200?205?210

Val?Gln?His?Pro?Asn?Gly?Asn?Lys?Glu?Lys?Asn?Val?Pro?Leu?Pro

215?220?225

Val?Ile?Ala?Glu?Leu?Pro

230

<210>4

<211>213

<212>PRT

＜213〉ethnic group IgF ab light chain

<400>4

Thr?Gln?Pro?His?Ser?Val?Ser?Glu?Ser?Pro?Gly?Lys?Thr?Val?Thr

1 5?10?15

Ile?Ser?Cys?Thr?Gly?Ser?Ser?Gly?Ser?Ile?Ala?Ser?Asn?Tyr?Val

20?25?30

Gln?Trp?Tyr?Arg?Gln?Arg?Pro?Gly?Ser?Ala?Pro?Thr?Thr?Val?Ile

35?40?45

Tyr?Glu?Asp?Ash?Gln?Arg?Pro?Ser?Gly?Val?Pro?Asp?Arg?Phe?Ser

50?55?60

Gly?Ser?Ile?Asp?Ser?Ser?Thr?Asn?Ser?Ala?Ser?Leu?Thr?Ile?Ser

65?70?75

Gly?Leu?Lys?Thr?Glu?Asp?Glu?Ala?Asp?Tyr?Tyr?Cys?Gln?Ser?Tyr

80?85?90

Asp?Ser?Ser?Asn?Trp?Val?Phe?Gly?Gly?Gly?Thr?Lys?Leu?Thr?Val

95?100?105

Leu?Gly?Gln?Pro?Lys?Ala?Ala?Pro?Ser?Val?Thr?Leu?Phe?Pro?Pro

110?115?120

Ser?Ser?Glu?Glu?Leu?Gln?Ala?Asn?Lys?Ala?Thr?Leu?Val?Cys?Leu

125?130?135

Ile?Ser?Asp?Phe?Tyr?Pro?Gly?Ala?Val?Thr?Val?Ala?Trp?Lys?Ala

140?145?150

Asp?Ser?Ser?Pro?Val?Lys?Ala?Gly?Val?Glu?Thr?Thr?Thr?Pro?Ser

155?160?165

Lys?Gln?Ser?Asn?Asn?Lys?Tyr?Ala?Ala?Ser?Ser?Tyr?Leu?Ser?Leu

170?175?180

Thr?Pro?Glu?Gln?Trp?Glu?Ser?His?Lys?Ser?Tyr?Ser?Cys?Gln?Val

185?190?195

Thr?His?Glu?Gly?Ser?Thr?Val?Glu?Lys?Thr?Val?Ala?Pro?Thr?Glu

200?205?210

Cys?Ser

Claims (3)

1. intestinal bacteria that produce the dimeric specificity targeting thrombolysis of the anti-D-in people source antibody, it is characterized in that by the half sleeve type PCR method human immunoglobulin gene that increases, cut with Xba I and Sac I enzyme respectively with phage plasmid pComb3H DNA with through purifying light chain PCR product then, the T4DNA ligase enzyme connects into pComb3H-L; The pComb3H-L and the purified heavy chain PCR product that will contain light chain gene again carry out Xho I and Spe I endonuclease reaction respectively, be connected to form recombinant phage plasmid pComb3H-HL with the T4DNA ligase enzyme, recombinant phage plasmid pComb3H-HL screens through the enrichment of D-dimer, after intestinal bacteria XL1-Blue is hatched, under the superingection of helper phage VCSM13, be built into the phage antibody combinatorial library again; Filter out the dimeric special strain of anti-human fibrin degraded product D-through the ELISA method.

2. described aminoacid sequence that contains the intestinal bacteria excretory light chain of antibody of the dimeric specificity targeting thrombolysis of the anti-D-in people source antibody of claim 1 is characterized in that:

S V S E S P G K T V T I S C T

G S S G S I A S N Y V Q W Y R

Q R P G S A P T T V I Y E D N

Q R P S G V P D R F S G S I D

S S T N S A S L T I S G L K T

E D E A D Y Y C Q S Y D S S N

W V F G G G T K L T V L G Q P

K A A P S V T L F P P S S E E

L Q A N K A T L V C L I S D F

Y P G A V T V A W K A D S S P

V K A G V E T T T P S K Q S N

N K Y A A S S Y L S L T P E Q

W E S H K S Y S C Q V T H E G

S T V E K T V A。

3. gene order that produces the light chain of the described people of claim 2 source targeting thrombolysis antibody is characterized in that:

TCTGTGTCGGAGTCTCCGGGGAAGACGGTAACCATCTCCTGCACC

GGCAGCAGTGGCAGCATTGCCAGCAACTATGTGCAGTGGTACCGG

CAGCGCCCGGGCAGTGCCCCCACCACTGTGATCTATGAGGATAAC

CAAAGACCCTCTGGGGTCCCTGATCGGTTCTCTGGCTCCATCGAC

AGCTCCACCAACTCTGCCTCCCTCACCATCTCTGGACTGAAGACT

GAGGACGAGGCTGACTACTACTGTCAGTCTTATGATAGCAGCAAT

TGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAGGTCAGCCC

AAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAG

CTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTC

TACCCGGGAGCCGTGACGGTGGCCTGGAAGGCAGATAGCAGCCCC

GTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAAC

AACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCTGAGCAG

TGGGAGTCCCACAAAAGCTACAGCTGCCAGGTCACGCATGAAGGG

AGCACCGTGGAGAAGACAGTGGCC。

Images